All In Biotech

Drug Trial Radar · NCT00684177

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL

Last checked: Nov 20, 2026Latest source record: Nov 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

508

Actual

Start

May 2008

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 26, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.

Conditions

  • Skin Infections, Bacterial

Interventions

  • Retapamulin Ointment, 1%Drug

    Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.

  • Placebo ointmentDrug

    Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy PopulationTime frame: Days 12-14

Locations

54 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Irvine, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Deerfield Beach, Florida

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Panama City, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Vero Beach, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Arlington Heights, Illinois

  • GSK Investigational Site

    Kansas City, Kansas

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Butte, Montana

  • GSK Investigational Site

    Teaneck, New Jersey

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    East Syracuse, New York

  • GSK Investigational Site

    Johnson City, New York

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Norristown, Pennsylvania

  • GSK Investigational Site

    Uniontown, Pennsylvania

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Bountiful, Utah

  • GSK Investigational Site

    Vienna, Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    Chivilocoy, Buenos Aires, Argentina

  • GSK Investigational Site

    Loma Hermosa, Buenos Aires, Argentina

  • GSK Investigational Site

    Curitiba, Paraná, Brazil

  • GSK Investigational Site

    Curitiba/Paraná, Paraná, Brazil

  • GSK Investigational Site

    Passo Fundo, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Bangalore, India

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.